Therapy Areas: Inflammatory Diseases
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
24 April 2025 - China-based LakeShore Biopharma Co Ltd (Nasdaq:LSB) announced on Wednesday that it has held the 2025 CSO (Contract Sales Organisation) Annual Meeting and the launch meeting of YSJA rab...
SynAct Pharma secures US patent allowance for resomelagon combination therapy in rheumatoid arthritis
23 April 2025 - Clinical stage biotechnology company SynAct Pharma AB (STO:SYNACT) announced on Wednesday that it has received a Notice of Allowance from the United States Patent and Trademark Office ...
NS Pharma's NS-229 granted US FDA Orphan Drug Designation for treatment of eosinophilic granulomatosis with polyangiitis
22 April 2025 - NS Pharma Inc, a subsidiary of Japan-based Nippon Shinyaku Co Ltd (TYO:4516), announced on Monday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ...
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
17 April 2025 - Dermatology company Sol-Gel Technologies Ltd (NASDAQ:SLGL) revealed on Thursday that it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (A...
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
16 April 2025 -

Biopharmaceutical company TNF Pharmaceuticals Inc (Nasdaq: TNFA) announced on Wednesday that it presented its oral TNF-alpha inhibit...

Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
16 April 2025 - US-based biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) on Tuesday reported positive interim data from the open-label portion of its Phase 2a clinical trial, CLEER-001,...